However, gliomas can acquire resistance to CSF-1R inhibition mediated by changes in the TME that lead to increased secretion of interleukin (IL)-4, a potent inducer of pro-tumor, alternatively activated TAMs, from CD8+ T cells and other cell types [31]. The gene discussed is IL4; the disease is central nervous system cancer.